C4 Therapeutics, Inc.
CCCC
$4.24
$0.163.92%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.33% | -12.37% | 1.02% | -10.57% | 16.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.33% | -12.37% | 1.02% | -10.57% | 16.55% |
| Cost of Revenue | -75.49% | -61.87% | -28.41% | -87.40% | -81.41% |
| Gross Profit | 105.56% | 24.86% | 17.03% | 121.96% | 119.46% |
| SG&A Expenses | -10.48% | -12.07% | -14.07% | -11.08% | -1.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.80% | -11.75% | -8.07% | -0.93% | 8.24% |
| Operating Income | 18.27% | 11.54% | 10.83% | -1.85% | -6.15% |
| Income Before Tax | 9.11% | -0.52% | 0.30% | -13.05% | -4.56% |
| Income Tax Expenses | -7.63% | -7.63% | -7.63% | -52.71% | -89.77% |
| Earnings from Continuing Operations | 9.11% | -0.51% | 0.31% | -12.88% | -3.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.11% | -0.51% | 0.31% | -12.88% | -3.44% |
| EBIT | 18.27% | 11.54% | 10.83% | -1.85% | -6.15% |
| EBITDA | 18.23% | 11.79% | 11.12% | -1.66% | -6.05% |
| EPS Basic | 36.86% | 19.60% | 10.50% | 1.95% | 16.71% |
| Normalized Basic EPS | 46.10% | 31.72% | 20.17% | 10.27% | 14.86% |
| EPS Diluted | 36.86% | 19.60% | 10.50% | 1.95% | 16.71% |
| Normalized Diluted EPS | 46.10% | 31.72% | 20.17% | 10.27% | 14.86% |
| Average Basic Shares Outstanding | 58.16% | 38.07% | 19.36% | 10.42% | 18.66% |
| Average Diluted Shares Outstanding | 58.16% | 38.07% | 19.36% | 10.42% | 18.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |